Cancer genomes are globally hypo methylated, a state associated with altered gene expression, chromosomal instability and loss of monoallelic imprinting 4 . By incompletely understood mechanisms, many promoter-associated CpG islands become hypermethyl ated in cancer, which is a mechanism of gene silencing 4 .
DNA methyltransferases (DNMTs) catalyze the conversion of cytosine to 5-methylcytosine. DNMT3A and DNMT3B add methyl groups to unmodified DNA, and DNMT1 maintains existing DNA methylation after cell division.
which characterize specific types of AML. Now, on page 309 of this issue, Zhu Chen, Sai-Juan Chen and colleagues identify recurrent somatic mutations in DNMT3A in AML 1 . Ley et al. 2 and Yamashita et al. 3 also recently identified DNMT3A mutations in AML.
DNA methylation and hematopoiesis
DNA methylation at the cytosine residue of the CpG dinucleotide is a covalent modification of DNA associated with gene silencing. CpGs cluster in 'islands' spanning the 5′ end of a gene.
Acute myeloid leukemia (AML) is a heterogeneous malignancy that can be classified by morphological, cytogenetic and molecular genetic criteria. Molecular studies have pinpointed recurrent somatic mutations in CEBPA, NPM1, FLT3, TET2, IDH1 and IDH2 and fusion proteins such as PML-RARα and CBFB-MYH11,
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new studies reveal that 20% of individuals with acute myeloid leukemia harbor somatic mutations in DNMT3A (encoding dna methyltransferase 3a). although these leukemias have some gene expression and dna methylation changes, a direct link between mutant dnMT3a, epigenetic changes and pathogenesis remains to be established. antimiR-21 was injected in mice, miR-21 was sequestered in a complex with the antimiR in kidney, liver and lung, and the miR-21 target BTG2 was upregulated. Similar functional results were obtained with an antimiR targeting miR-122.
The specificity and potency of these small antimiRs makes them strong drug candidates for treating diseases in which inhibition of specific miRNAs or miRNA families could have a therapeutic benefit. It is important to better understand the targets of a given miRNA before applying antimiRs in a therapeutic setting. Inhibition of a single protein can have profound effects on a pathway of genes responsive to that protein. The seedtargeting antimiRs are already in a druggable format, eliminating the problem of delivery formulations associated with small interfering RNA (siRNA)-based therapeutics. The phophorothioate linkages and LNA stability allow these to be systemically administered in the absence of a specific carrier. In addition, the relatively small size of seven to eight nucleotides greatly reduces manufacturing costs over other therapeutic antisense and siRNA drugs. The discovery of miRNAs in mammals took place less than a decade ago, but their central importance in development and cellular physiology has brought them to the forefront of potential drug targets. Tiny antimiRs have the potential to become the first drugs based on RNA interference.
COMPETEING FINANCIAL INTERESTS
The author declares no competing financial interests.
and resulted in upregulation of a miR-21 target protein. Shorter oligos had less potency, and 8-mers with mismatches or 8-mers targeting other regions of miR-21 had little or no inhibitory effect.
How do these tiny oligos block miRNA function? Do they trigger degradation or simply serve as steric inhibitors? Obad et al. 3 present evidence that steric blocking of the seed sequence is the answer, as the antimiRs form strong hybrids with complementary miRNA seeds and are coimmunoprecipitated with Argonaute 2 (Ago2), a major component of the RNA-induced silencing complex (RISC) that directly binds miRNAs 11 .
The idea of only using seed sequences for targeted inhibition of miRNA function predicts that miRNA family members sharing identical seeds would be targeted simultaneously by a complementary antimiR. To investigate this possibility, Obad et al. 3 tested all nine let-7 family members with the same antimiR. They carried out these studies using a reporter gene assay in which the reporter harbored the let-7 family seed complement, and each family member was shown to independently downregulate the reporter. To validate the ability of the antimiR to inhibit all family members' functions, they showed that this inhibition was blocked for each of the let-7 members when the cells were also treated with the antimiR to the let-7 seed.
Tiny antagomirs as drugs?
The final functional test for these seedtargeting LNAs was their ability to downregulate miRNA function in vivo. When volume 43 | number 4 | april 2011 | nature genetics reported a hybridization-based resequencing analysis of 19 AMLs and the identification of a somatic mutation of DNMT3A.
As hematopoietic differentiation can proceed in the absence of DNMT3A, the pathogenic mechanism of DNMT3A mutation remains enigmatic. Almost all DNMT3A mutations were heterozygous, about half occurred at position Arg882 and yielded a partially defective enzyme and many others led to truncated proteins devoid of catalytic activity 1 1 found ~4% of genes differentially expressed. Interestingly, several HOXB genes, as well as IDH1, were upregulated in DNMT3A mutant AML. However, only HOXB2 had a substantial decrease in promoter methylation, suggesting that gene deregulation also occurred through another mechanism. MLL fusion proteins that activate HOX expression were not found in leukemias with DNMT3A mutation 1 , suggesting that their oncogenic actions might be redundant.
DNMT3A forms complexes with multiple transcriptional components, including histone methyltransferases and deacetylases (Fig. 1) 10 . Haploinsufficiency of DNMT3A or production of a disabled protein might alter the stoichiometry or stability of a DNMT3A protein complex and affect gene expression without a striking effect on DNA methylation. Given that DNMT3A mutant AML does not have a common pattern of gene expression, these effects might be subtle or pleiotropic. Alternatively, the function of DNMT3A mutations might be affected by coincident mutations, like those in FLT3 or NPM1. Further biochemical experiments and the creation of mouse models will be required to determine if DNMT3A mutations result in a loss of function, yield dominant negative proteins or generate neomorphic enzymes.
DNMT1, DNMT3A
and DNMT3B expression generally rises during hematopoietic differentiation 5 . A genome-wide survey of methylation in hematopoiesis revealed that myeloid differentiation was associated with global loss of methylation, whereas lymphoid cells gained methylation 6 . Mouse studies showed that Dnmt1 is required for hematopoietic stem cell self renewal, regulation of proliferation and normal myeloid and lymphoid differentiation 7, 8 . By contrast, deletion of Dnmt3a and Dnmt3b in mouse hematopoietic stem cells impaired stem cell self renewal but not lineage determination 9 . Given the requirement for DNMT3A for self renewal, the discovery of frequent DNMT3A mutations in AML 1-3 is somewhat surprising.
DNMT3A and epigenetic alterations
Yan et al. 1 sequenced the leukemia and matched bone marrow remission exomes of nine individuals with AML (specifically, the M5 subtype of AML) and identified several recurrently mutated genes, including GATA2, NSD1 and DNMT3A, genes which all encode gene regulatory proteins. DNMT3A mutations were often found in leukemias with mutations in NPM1, FLT3, IDH1 or IDH2 but were almost never found in leukemias with PML-RARα, RUNX1-RUNX1T1 or CBFB-MYH11 fusion proteins. The authors also looked at other leukemia subtypes and found DNMT3A mutations in myelomonocytic AML. Somatic DNMT3A mutations in AML were also recently reported by two other groups. Ley et al. 2 sequenced an AML genome and identified somatic DNMT3A mutations in 22% of AMLs. Both Ley et al. and Yan et al. reported that DNMT3A mutations were associated with a poor prognosis 1,2 . Yamashita et al. 3 
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Histone H3 DNA methylation Figure 1 Model of DNMT3A activity. The DNMT3A protein complex is associated at promoters of silent genes in a complex with histone methyltransferase (HMT), histone deacetylase (HDAC) and DNA methyltransferase 3L (DNMT3L). These promoters are marked by DNA methylation, histone deacetylation and histone 3 lysine 9 methylation (K9me3). Closed circles represent methylated CpG dinucleotides.
Epigenetic deregulation in AML Genome-wide surveys showed that AML can be classified on the basis of patterns of promoter methylation 11 . AML subtypes characterized by PML-RARα and CBFB-MYH11 fusion proteins, or by loss-of-function mutations in CEBPA, show distinct patterns of promoter methylation that may be related to the interaction of these transcription factors with DNMTs 12 . Although DNMT3A mutation did not yield a specific pattern of altered DNA methylation, individuals with AML with somatic mutations of TET2, which encodes an enzyme that converts 5-methylcytosine to 5-hydroxymethycytosine 13, 14 , showed distinct patterns of promoter hypermethylation, as did individuals with IDH1 and IDH2 mutations 15 . IDH1 or IDH2 and DNMT3A mutations can occur together in AML, suggesting that these genes have nonoverlapping functions.
Genome sequencing is opening a new and complicated phase toward understanding the molecular pathogenesis of AML. The discovery of DNMT3A mutations in AML would seem to imply that aberrant epigenetic regulation is critical for pathogenesis, but the exact link, whether it be altered gene expression or genome stability, has yet to be uncovered. Other key questions include: why is only DNMT3A mutated in AML if DNMT3B has a similar function? Why are DNMT3A mutations concentrated in specific AML subtypes and associated with poor prognosis? What aspects of leukemia biology can be attributed to DNMT3A mutation? And, most critically, can specific therapies be designed against this form of AML?
